Business News • PR NewsWire • Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

PARIS, June 4, 2011 /PRNewswire-FirstCall/ -- - Results of Phase III SAVE-ONCO Study Selected for "Best of ASCO 2011" - - Venous Thrombo-embolism Affects Up to 1 in 5 Cancer Patients And Chemotherapy Further Increases this Risk Sanofi (EURONEXT: SAN and NYSE: SNY) announced today

View More : http://www.prnewswire.com/news-releases/sanofis-investigational-semuloparin-in-cancer-patients-initiating-chemotherapy-s...

Releted News by prnewswire

"Historic Victory for Workers" as Connecticut Legislature Completes Work on Paid Sick Days Bill; Governor Poised to Make Connecticut First State to Guarantee Workers the Right to Earn Paid Sick Days

Learning ZoneXpress Unveils USDA MyPlate Products to Use in the Classroom

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64% Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy

Full Speed Ahead! The National WWII Museum Unveils New $3.2 Million Restoration Pavilion

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting